http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101856603-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0636 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0646 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0645 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5067 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5014 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0783 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0786 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 |
| filingDate | 2015-04-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101856603-B1 |
| titleOfInvention | Immunotoxicity verification techniques using human stem cell-derived hepatocytes |
| abstract | The present invention relates to a method for immunological hepatotoxicity screening using human stem cell-derived hepatocytes, which comprises administering to a hepatocyte differentiated from human stem cells acetaminophen (APAP) or PPAR gamma agonist (Troglitazone), rosiglitazone (Cytokine) secreted by the hepatocyte, and the cytokine, chemokine and lipid mediator secreted by the immune cells were identified. Secondary hepatotoxicity (Immunotoxicity). |
| priorityDate | 2015-04-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 680.